The In Vivo team recently put a spotlight on innovation that might disrupt the pharma and medtech markets. Thinking about novel developments today that will impact the life sciences sector in the near future, we explored interesting new science, the convergence of R&D and technology, as well as what the future of surgery might look like.
Under this theme, leaders from the UK’s Rosalind Franklin Institute spoke to In Vivo about what it means to seek truly ground-breaking innovation in 2021. Only three years old, the Franklin has big plans to go after transformative technologies in health care, using a “factor of 10” principle to measure its success.
“We have this rule of thumb ‘factor of 10’ guide,” chief operating officer Paul McCubbin explained. The researchers ask, ‘If...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
